Australia's most trusted source of pharma news
Friday, 22 September 2017
Lost Your Access?
Chem Warehouse entity hikes profit
: The entity believed to control around half of Chemist Warehouse has shown a solid profit increase but with a major international expansion on the horizon, it's likely to need it.
Clinical trials documentary dispels "misconceptions"
First In Human
, a six-part TV documentary that follows four patients through their clinical trial experiences, airs on Australian TV soon.
Local pharma hostage to global pricing says PBAC chief
: High prices still a significant stumbling block, PBAC chair Professor Andrew Wilson tells
Pharma in Focus
Big pharma scouting Aust for pipeline
: Big pharma 'scouts' and private equity groups are visiting Australia more frequently in the search for new pipeline hopefuls, say two experts in the area.
Link between asthma drug and nightmares strengthens
: More data showing a link between generic asthma drug montelukast and adverse neuropsychiatric reactions have been reported in a new study from the Netherlands.
Pfizer rebuffs generic competition
: Customers contacting Pfizer about a better price on its sedative
tipped the pharmaco off to a generic competitor being launched, the Federal Court has heard.
Job hunters in pharma declining
: Employees in the Australian pharmaceutical industry are staying put in their positions with movement in the sector dropping to a three year low.
Pfizer stays on top at Prime Awards
: Pfizer managed a repeat of last year, winning four gongs at the Prime Awards in Sydney last night, while GSK and Astellas walked away with two gongs apiece.
What's a pharma boss worth
: What can a pharma boss expect to earn in 2017 - and does gender influence pay packets at the top.
Women achieving equal pay in Aussie pharma
: Women are coming of age in Australian pharma earning the same as their male colleagues, but flexible working conditions remain more important to women than men.
TGA approvals lag for 2017 but rallying in Q3
: This year's tally of new drug registrations remains well below previous years but an uptick in the September quarter may hint at a change in pace for the sluggish ARTG.
Biosims, flu vaxes escape 'black triangle'
: Biosimilars and influenza vaccines have been made exempt from the new black triangle scheme, although new medicines will bear the mark for five years from January.
Challenges await incoming Novartis, Teva CEOs
: Incoming CEOs anointed to take over the top jobs at pharma giants Novartis and Teva are facing some big challenges, with plenty of advice being thrown around.
Bayer hits back at Novartis in eye stoush
: Bayer Australia has issued a strong response after Novartis' CMO claimed macular degeneration drug
had outperformed Bayer's
in an Australian trial.
AbbVie builds pipeline at both ends
: AbbVie is working hard to replace immunology blockbuster
, with plans to file anti-cancer drug
as a combination while investing in an early-stage neurology company.
CHMP recommends seven new drugs, four extensions
This week's CHMP meeting saw therapies from GSK, Janssen and Tesaro positively recommended for approval in the European market.
Queue for PBS listing stretches back years
With drugs waiting in the wings for PBS listing more than two and a half years after being recommended, the road to reimbursement remains a long and winding one and for some, it's a road to nowhere.
Pfizer registers meningo B vax
Pfizer has registered meningococcal B vax
on the ARTG making it the second vaccine for the disease after GSK's
Events & Conferences
© 2003 - 2017 Lush Media
Pharma in Focus
Jolly Good Design